NSI-189
Cas No.: 1270138-40-3
What is the NSI-189?
The formulation of NSI-189 (NSI-189 phosphate, benzylipiperidine-aminopyridine) is (4-benzylpiperidin-1-yl)-(2-(3-methylbutylamino)pyridin-3-yl)methanone). This organic compound was synthesized in 2009 and was initially developed as a drug for depression. However, it turned out that the compound has nootropic effects and supports neurogenesis processes.
Application of NSI-189
The product was developed to treat depressive conditions, and the antidepressant effect of the product is said to be due to the stimulation of neurogenesis in the hippocampus. Such effects of the product have been confirmed in clinical trials. Indeed, it turned out that people with depression who were given the drug at doses of 40, 80 or 120 mg for 4 weeks showed significant improvement in their clinical condition.
The product can be used to improve cognitive abilities – memory, concentration, information processing. In addition, the product can benefit mental well-being, add energy and increase motivation for action.
Mechanism of action
What stands out most about the formula is its ability to enhance long-term synaptic strengthening, which ultimately means improved neuroplasticity. Levels of neurotrophic factors such as BDNF increase. More connections are formed between neurons and this translates into efficient transmission of nerve impulses. The product can stimulate the processes of neurogenesis, mainly in the hippocampus, and it is this part of the brain that undergoes atrophy in the course of depression. Another distinguishing feature of the product is that it has no effect on neurotransmitter systems, such as the cholinergic, dopaminergic systems. This is how many nootropic preparations, such as Ladasten, work.
NSI-189 dosage.
The dosage that has been used most often in clinical trials and that has proven to be the most effective is 40 mg taken 1 to 3 times daily. The compound is water-soluble, so the formula is best taken on an empty stomach or between meals.
To increase its effectiveness, the product can be combined with supplements such as L-Dopa, rhodiola rosea, taurine or uridine.
References:
- M Fava et al. “A Phase 1B, randomized, double-blind, placebo-controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients” Mol Psychiatry. 2016 Oct; 21(10): 1372-1380; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030464/
- Allen B.D., Acharya M.M., Lu C. et al. Remediation of Radiation-Induced Cognitive Dysfunction through Oral Administration of the Neuroprotective Compound NSI-189. Radiation Research (2018); https://europepmc.org/article/MED/29351056
- Tajiri N., Quach D.M., Kaneko Y. et al. NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats. Journal of Cellular Physiology (2017); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518191/
